A still-sluggish activity ...
During Q3 2016, SIPHAT’s revenues witnessed a drop of 9.9%, from TND9.704m in Q3 2015 to TND8.741m. This drop is mainly due to a 22.9% decrease in pharmaceutical sales. The production was down by 15.6% to TND7.445m on the back of a deterioration in the hospital model production which reached TND2.565m (-38% yoy).Over the first nine months of 2016, the company’s revenues were set at TND27.6m vs. TND30.5m a year earlier, i.e.
AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.